Foley Hoag’s nationally recognized, full-service Life Sciences law practice represents more than 2,000 Fortune 100, middle-market and emerging biotechnology, pharmaceutical, medical device and HealthTech companies, medical-research institutes and patient organizations. By drawing on the talents of a wide variety of professionals, many of whom have had previous careers as Ph.D. scientists, physicians and legislative advisors, we help clients navigate the complex waters associated with the development, approval, commercialization, reimbursement and coverage of innovative medical products and services.
Our Digital Health Practice advises leading companies across the digital health spectrum, from digital treatment therapeutics, to cloud-based healthcare services, to tech-driven health insurance platforms, to AI tools for drug discovery. As digital health continues to evolve, our team is trusted to dispense insight related to all matters facing companies and investors in the digital health space, including complex regulatory, reimbursement and coverage challenges, intellectual property issues, licensure, protection of data and opportunities for growth.